Moreover, a patient with diffuse large B cell lymphoma who received focal RT (in 5 fractions of 4 Gy each) to skin lesions in a leg (with palliative intent) prior to CD19-targeting CAR T (CART19) cells experienced systemic relapse a few months after CAR T cell therapy (with CD19 negative disease), with the sole exception of the irradiated area [11]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.